This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome

This study has been completed.
Sponsor:
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Acucela Inc.
ClinicalTrials.gov Identifier:
NCT01632137
First received: June 28, 2012
Last updated: April 17, 2014
Last verified: April 2014
  Purpose
The purpose of this study is to evaluate the efficacy and safety of rebamipide ophthalmic suspension in subjects with dry eye syndrome.

Condition Intervention Phase
Dry Eye Syndrome Drug: Rebamipide 2% ophthalmic suspension Drug: Placebo (vehicle) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Study to Determine the Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome

Further study details as provided by Acucela Inc.:

Primary Outcome Measures:
  • Primary ocular sign: Fluorescein corneal staining total score [ Time Frame: 4 weeks ]
  • Primary ocular symptom: Worst ocular symptom severity score [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Fluorescein corneal staining total score [ Time Frame: 2 weeks ]
  • Worst ocular symptom severity score [ Time Frame: 2 weeks ]

Enrollment: 564
Study Start Date: June 2012
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo (vehicle) Drug: Placebo (vehicle)
Instill one drop into each eye 4 times a day for 4 weeks.
Experimental: Rebamipide 2% ophthalmic suspension Drug: Rebamipide 2% ophthalmic suspension
Instill one drop into each eye 4 times a day for 4 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of dry eye-related ocular symptoms for at least 20 months.
  • Meet protocol-defined criteria for corneal and conjunctival staining.
  • Meet protocol-defined criteria for ocular discomfort.

Exclusion Criteria:

  • Active anterior segment ocular disease other than dry eye syndrome.
  • Inability to suspend the use of topical ophthalmic medications throughout the duration of the study.
  • Inability to suspend the use of contact lenses for the duration of the study.
  • Judged by the investigator to be ineligible for the study because of a past or concurrent systemic disease, or safety concerns.
  • Received any other investigational product within 4 months before the screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01632137

  Show 34 Study Locations
Sponsors and Collaborators
Acucela Inc.
Otsuka Pharmaceutical Co., Ltd.
Investigators
Study Director: Acucela Medical Monitor Acucela Inc.
  More Information

Responsible Party: Acucela Inc.
ClinicalTrials.gov Identifier: NCT01632137     History of Changes
Other Study ID Numbers: ACU-RED-301
Study First Received: June 28, 2012
Last Updated: April 17, 2014

Additional relevant MeSH terms:
Syndrome
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Disease
Pathologic Processes
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Rebamipide
Anti-Ulcer Agents
Gastrointestinal Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Enzyme Inhibitors

ClinicalTrials.gov processed this record on July 25, 2017